CN112043640B

CN112043640B - Composition and application thereof in preparation of anti-glycosylation cosmetics

Info

Publication number: CN112043640B
Application number: CN202011000747.9A
Authority: CN
Inventors: 戴跃锋; 何广文; 颜少慰; 马晓瑜
Original assignee: Syoung Cosmetics Manufacturing Co Ltd
Current assignee: Syoung Cosmetics Manufacturing Co Ltd
Priority date: 2020-09-22
Filing date: 2020-09-22
Publication date: 2023-05-23
Anticipated expiration: 2040-09-22
Also published as: CN112043640A

Abstract

The invention relates to the technical field of cosmetics, in particular to a composition and application thereof in preparing an anti-glycosylation cosmetic. The composition provided by the invention consists of ALISTIN, symCalmin, ectoin, methyl silanol mannuronate, black tea extract, carnosine and extremely repairing peptide. The composition starts from biological and physicochemical reactions in the body in three time periods of a pre-Schiff base generation stage, an early glycosylation product generation stage and a later glycosylation end product formation stage respectively. Through the time sequence approach, the multi-dimensional cooperation promotes the organism anti-sugar capability and repairs the protein structure damage caused by skin saccharification, lightens the skin and increases the elasticity. The components are matched with each other to realize good inhibition effect, and the components are indispensable.

Description

Composition and application thereof in preparation of anti-glycosylation cosmetics

Technical Field

The invention relates to the technical field of cosmetics, in particular to a composition and application thereof in preparing an anti-glycosylation cosmetic.

Background

With age, all organs of the human body undergo degradation, aging changes, and the skin also undergoes great changes in structure and function. Today, most scholars differentiate skin aging into natural aging and photoaging. Wherein natural aging is a natural, unavoidable aging process that occurs in the skin as the human body ages. In the natural aging process, the epidermis is often thinned, the network ridges become flattened, the shared interface area at the junction of the epidermis and the dermis is reduced, and the skin fragility is increased. In the skin, the structure and number of different cells are changed, and the gene expression, biological factors and protein synthesis capacity are reduced. The skin collagen grid becomes compact and the elastic fiber is obviously decomposed, so that the skin is loose, sagged, wrinkled and the like. At the same time, the content of matrix proteoglycan is reduced, so that the hydration capability is reduced, and the skin aging appearance is formed.

The natural aging of skin is a complex process, and there are mainly 5 mechanisms of aging process, namely: oxidative stress, mitochondrial damage, cellular senescence, contaminant damage, and skin glycation. Among them, skin glycation has been widely focused in recent years, and has become a research hotspot. Glucose or other carbohydrate molecules in the body adhere to proteins by mistake, causing protein denaturation, a detrimental reaction that contributes to aging. Specifically, the addition of the reducing amino group at the end of the macromolecule and the aldehyde group in sugar molecules such as glucose form a reversible Schiff base, and the reaction is rapid and highly reversible; after a few days, the unstable Schiff base gradually undergoes a rearrangement reaction and forms a relatively stable aldehyde amine product, and the aldehyde amine product accumulates on the protein to form an early glycosylation product; finally, the product undergoes a series of dehydration and rearrangement reactions to produce highly reactive carbonyl compounds, such as methylglyoxal, which react with the free amino groups of the protein to produce advanced glycation end products (AGEs). The AGEs generated can be combined with free amino groups on adjacent proteins in a covalent bond mode to form an AGE cross-linked structure.

AGEs and their protein addition products are very stable and irreversible, thus disrupting normal protein structure and function. For the human body, glycosylation can thicken and harden the arterial wall, and is easy to break, thereby causing hypertension, heart disease, kidney disease and cerebrovascular disease; can cause adjacent lens proteins to twist together, causing clouding and degeneration of the lens, and causing senile cataract. For human skin tissues, the enzyme activity function becomes low in the glycosylation process, and the oxidative stress sensitivity of cells is enhanced, so that the cells are more vulnerable to damage; in the early glycosylation product forming process, the composition can interact with various cell surface AGE receptors, so that oxidative damage is easy to trigger, and simultaneously, the increase of free radicals is accompanied with inflammatory reaction, so that the balance of the whole physiological process is broken, and metabolism is disturbed. And when the final product of late glycosylation is formed, the free amino groups on proteins important to the skin, such as collagen and elastin, are combined with covalent bonds to form an AGE cross-linked structure. The reaction is irreversible, so that the density of a crosslinked network is improved, and the chemical structure and corresponding biomechanical and physiological functions of the crosslinked network are destroyed. From the appearance of the skin, yellowing, dullness, sagging, wrinkles, etc. of the skin can be observed.

Currently, the mechanisms of the aging process are subdivided, so that the anti-aging and skin repair are performed from different subdivision mechanisms. For the anti-glycosylation process, a single strategy is usually adopted at present, only the final product AGE is focused, and the AGE is decomposed by adopting medicines, so that only partial inhibition effect is usually achieved, and the whole effect is ignored; or limited to the ways of scavenging free radicals, resisting oxidation, etc., and generally deal with symptoms at a certain reaction node, the whole reaction process cannot be comprehensively considered, so that the final anti-glycosylation effect is poor.

Glycosylation is a long-term process with a time effect, with different characteristics at each stage. The Schiff base synthesis stage and the glycosylation early-stage product synthesis stage are characterized in that the generated product has inhibitive performance and reversibility, and the extracellular matrix microenvironment can be changed through the introduction of active substances, so that the inhibition and reversal reaction are carried out; the crosslinking density of fibrin and elastin is obviously improved in the later-stage advanced glycosylation end product forming stage, and the process is difficult to reverse, but can be relieved and partially repaired by means of protein binding competition, degradation and the like. In view of this, in the strategy of considering the anti-glycosylation, the whole process should be comprehensively considered, and according to the characteristics of different stages, appropriate functional substances are respectively adopted to play roles of prevention, reversion and repair; with glycosylation sequence as core, anti-glycation and skin repair are performed in multiple dimensions.

Disclosure of Invention

In view of the above, the technical problem to be solved by the present invention is to provide a composition and its use in the preparation of anti-glycosylated cosmetics, the composition acting from multiple targets with remarkable effect.

The composition provided by the invention consists of ALISTIN, symCalmin, ectoin, methyl silanol mannuronate, black tea extract, carnosine and extremely repairing peptide.

The composition provided by the invention comprises the following components in parts by mass:

in some embodiments, the composition comprises the following components in parts by mass:

the composition starts from biological and physical-chemical reactions in vivo in three time periods of a pre-Schiff base generation stage, an early glycosylation product generation stage and a later glycosylation end product formation stage respectively: pre-activating protease activity in vivo, scavenging excessive free radicals, and thereby preventing saccharification reaction; the early glycosylation product generation stage promotes the reverse reaction by relieving oxidative stress and reducing inflammatory reaction, so as to realize the reverse of early transition products; in the formation stage of the advanced glycosylation end product, skin repair is carried out from the two aspects of avoiding protein non-ideal crosslinking reaction and promoting collagen synthesis. Through the time sequence approach, the multi-dimensional cooperation promotes the organism anti-sugar capability and repairs the protein structure damage caused by skin saccharification, lightens the skin and increases the elasticity.

The invention provides an application of a composition in inhibiting protein saccharification reaction.

In vitro experiments show that the composition can more effectively inhibit the generation of fructosamine and AGEs, the inhibition rate can reach 82.72%, and the composition has obvious synergistic effect after the components are mutually matched. Compared with a plurality of control samples, the composition has more remarkable effect, which proves that the components in the composition provided by the invention are matched with each other to realize good inhibition effect, and the components are indispensable.

The invention provides an application of a composition in preparing anti-aging cosmetics.

The anti-aging includes: reducing skin erythema, reducing skin yellowing, increasing skin moisture content, and/or increasing skin elasticity.

In vivo experiments show that the composition provided by the invention can continuously improve the moisture content of skin, which indicates that the repair of the barrier function of the skin is improved. And the erythema problem generated by the skin inflammation is relieved, and the damage of inflammatory factors and free radical induced glycosylation reaction to the tissue structure is reduced. So that glycosylation reaction of collagen of skin is relieved, consumption of collagen by glycosylation reaction is reduced, and elasticity problem of skin is improved. Finally, the skin color is reflected on the skin color, so that the yellowness of the skin is reduced. Compared with a plurality of control samples, the composition has more remarkable effect, which proves that the components in the composition provided by the invention are matched with each other to realize good inhibition effect, and the components are indispensable.

The invention provides an anti-aging cosmetic, which contains the composition.

In the cosmetic, the mass fraction of the composition is 1.8-19.5%.

The cosmetic consists of the following components in percentage by mass:

in some embodiments, the cosmetic consists of the following components in percentage by mass:

/>

the cosmetic disclosed by the invention is a facial mask, and comprises facial mask liquid and facial mask matrix.

The auxiliary materials in the mask liquid are reasonably selected, so that the stability of each component can be maintained to the greatest extent, and the absorption of the skin to the active ingredients is promoted.

The preparation method of the cosmetic comprises the following steps:

step 1: sequentially adding glycerol, 1, 2-pentanediol, butanediol, PEG/PPG-17/6 copolymer, acrylic acid (esters) type/C10-30 alkanol acrylate cross-linked polymer and PEG-11 methyl ether polydimethylsiloxane into water, stirring and dissolving;

step 2: adding arginine at 75deg.C, stirring for dissolving, and vacuum maintaining for 10min.

Step 3: cooling to 40-45 deg.c, adding ALISTIN, symCalmin, ectoin, methyl silanol mannuronate, black tea extract, carnosine, very good repairing peptide and PHL successively, stirring and dissolving to obtain the cosmetics.

In the invention, the stirring condition in the step 1 is 10-40HZ, and the stirring is stopped after heating to 75 ℃; the stirring condition in the step 2 is 10-30HZ, and stirring is carried out until the mixture is dissolved; the stirring condition in the step 3 is 10-30HZ, and stirring is carried out for 5min.

The composition provided by the invention consists of ALISTIN, symCalmin, ectoin, methyl silanol mannuronate, black tea extract, carnosine and extremely repairing peptide. The composition starts from biological and physicochemical reactions in the body in three time periods of a pre-Schiff base generation stage, an early glycosylation product generation stage and a later glycosylation end product formation stage respectively. Through the time sequence approach, the multi-dimensional cooperation promotes the organism anti-sugar capability and repairs the protein structure damage caused by skin saccharification, lightens the skin and increases the elasticity. The components are matched with each other to realize good inhibition effect, and the components are indispensable.

Drawings

FIG. 1 shows the increase in skin moisture content;

FIG. 2 shows reduction of skin erythema;

FIG. 3 shows the increase in skin elasticity;

figure 4 shows the reduction in skin yellowness.

Detailed Description

The present invention provides a composition and its use in the preparation of anti-glycosylated cosmetics, which can be achieved by those skilled in the art, with the aid of the present disclosure, by suitably modifying the process parameters. It is expressly noted that all such similar substitutions and modifications will be apparent to those skilled in the art, and are deemed to be included in the present invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the relevant art that the invention can be practiced and practiced with modification and alteration and combination of the methods and applications herein without departing from the spirit and scope of the invention.

The test materials adopted by the invention are all common commercial products and can be purchased in the market.

ALISTIN, decarboxylated carnosine HCL (Decarboxy Carnosine HCL), commercially available as AListin, is a peptide with anti-glycation and anti-oxidation properties. Has catalase-like activity, can convert harmful LOOH (lipid peroxide) into nontoxic alcohol LOH, and can prevent protein from being degraded by toxic free radicals.

SymCalmin mainly comprises ascorbyl palmitate and hydroxy phenyl propionamide benzoic acid, and the ascorbyl palmitate is converted into vitamin C after percutaneous absorption, so that free radicals in skin can be greatly reduced, skin injury is obviously reduced, and the effect of protecting skin is achieved. The hydroxy phenyl propionamide benzoic acid has anti-inflammatory and antioxidant effects, and can reduce the damage of tissue structure caused by skin inflammation.

Ectoin, also known as "salt tolerant bacterial extract", is derived from halophil (Halomonas Elongata) and its main component is tetrahydropyrimidine carboxylic acid.

The main components of the black tea extract comprise tea polyphenol, theaflavin and the like, and the black tea extract has strong antioxidation.

Carnosine, beta-alanyl-L-histidine, is a dipeptide consisting of two amino acids beta-alanine and L-histidine,

the polar repair peptide (WKPep SRMpeptides) is a composition of 6 polypeptides, comprising tripeptide-1, palmitoyl tripeptide-5, hexapeptide-9, palmitoyl pentapeptide-4, palmitoyl tetrapeptide-7, palmitoyl tripeptide-1. Wherein palmitoyl tripeptide-5 is capable of activating a cytokine TGF-beta signaling pathway, thereby promoting collagen synthesis and inhibiting matrix metalloproteinase activity; palmitoyl pentapeptide-4 stimulates the synthesis of collagen and elastin in the dermis layer of the skin; palmitoyl tetrapeptide-7 can delay and inhibit the production of excess cellular interleukins, thereby inhibiting inflammatory reactions and glycosylation damage; palmitoyl tripeptide-1 acts on the dermis layer to promote synthesis of collagen and glycosaminoglycan.

Methylsilanol mannuronate is synthesized from semi-natural silanol and mannuronate, and can be used as skin conditioner to improve water retention of epidermis.

In the present invention, according to the cosmetic classification principle, cosmetics can be classified into: cleaning cosmetics, nursing cosmetics and beautifying/finishing cosmetics. The cleaning cosmetic is applied to the surface of human body (such as epidermis, hair, nail, lips, etc.) by applying, spraying or other similar methods, and has effects of cleaning and hygiene or eliminating unpleasant odor. The cosmetic is applied to human body surface (such as epidermis, hair, nail, lips, etc.) by applying, spraying or other similar methods. The cosmetic/decorative cosmetic is applied to the surface of human body (such as epidermis, hair, nail, lips, etc.) by painting, spraying or other similar methods, and has effects of caring skin, finishing, and increasing human body charm.

Among the cleansing cosmetics applicable to the skin include: facial cleanser, cleansing water (milk), cleansing cream (honey), facial mask, toilet water, itch powder, talcum powder or bath lotion; skin-applicable care cosmetics include skin cream, lotion or lotion; skin-applicable cosmetic/finishing cosmetics include: powder cake, rouge, eye shadow, eyeliner (liquid), eyebrow pencil, perfume or cologne; hair-applicable cleansing cosmetics include shampoos, creams or shave creams; the hair-suitable care cosmetics include hair conditioner, hair cream, hair oil/wax or hair treatment cream; cosmetic/finishing-type cosmetics for which hair is suitable include: styling mousse/gel, hair dye, permanent wave, mascara solution (cream), hair restorer or depilatory; cleaning cosmetics suitable for nails include nail washing liquid; the care cosmetics suitable for nails comprise nail protection water (cream) and nail hardening agent; nail-applicable make-up/finishing cosmetics include nail polish; the cleansing cosmetic suitable for lips comprises a lip cleansing liquid; lip care cosmetics include lip balm; lip-applicable cosmetic/make-up products include: lipstick, lip gloss or lip pencil.

The invention is further illustrated by the following examples:

examples

Test samples were prepared according to the formulations in table 1:

TABLE 1 cosmetic formulation (%)

The patent sample is used as a representative to illustrate the specific preparation process of the anti-glycosylation mask, which comprises the following steps:

1) Sequentially adding glycerin, 1, 2-pentanediol, butanediol, PEG/PPG-17/6 copolymer, acrylic acid (esters)/C10-30 alkanol acrylate cross-linked polymer and PEG-11 methyl ether polydimethylsiloxane into water to uniformly disperse, stirring for 10-40HZ, heating to 75 ℃ to dissolve completely, and continuously stirring;

2) Slowly adding arginine at 75deg.C, stirring for 10-30Hz until dissolution is completed, and vacuum maintaining for 10min.

3) Cooling to 40-45deg.C, sequentially adding ALISTIN, symCalmin, ectoin, methylsilanol mannuronate, black tea extract, carnosine, extremely repairing peptide and PHL, stirring at 10-30HZ for 5min; and (5) discharging.

4) And (5) canning 25ml of the material body into an aluminum plastic bag filled with facial mask paper, and sealing.

In vitro glycation inhibition experiments

Experimental reagent: PBS buffer (PH=7.4), filter sterilized glucose (Glu) solution at 1M concentration, filter sterilized 0.1M, PH 10.8.8 carbonate buffer, nitrotetrazolium chloride (NBT) carbonate buffer, bovine serum albumin

The experimental method comprises the following steps:

1. PBS buffer (pH 7.4) was prepared

2. The glucose concentration is 200mM, the final concentration of bovine serum albumin is 40g.L-1, and the reaction system is subjected to antibiosis by using 2000u.L-1 green streptomycin double-antibody liquid. Incubation was carried out at 37℃for 2-8 weeks, and the effect of glucose on the non-enzymatic glycation reaction of the protein was observed.

3. Determination of early glycated proteins (fructosamine): after incubation of the reaction system at 37℃for 2 weeks, 0.05ml of the reaction mixture was taken, 4ml of NBT was added, the reaction was terminated with 0.1ml of 15% acetic acid and a cold bath after incubation at 37℃for 15 minutes, and absorbance was measured at a wavelength of 530 nm.

4. Determination of saccharification end products (AGEs): after incubation of the reaction system for 8 weeks at 37℃the absorbance was measured at a wavelength of 400 nm.

5. Control group: 1) The complete saccharification reaction system without the test sample is added, and the absorbance is recorded as 1A; 2) Bovine serum albumin control, absorbance recorded as 2A; 3) Adding a test sample and not adding a saccharification system of bovine serum albumin, wherein the absorbance is recorded as 3A; 4) Adding a saccharification system without glucose into the test sample, and recording the absorbance as 4A;

test group: and adding a complete saccharification reaction system of the test sample, wherein the absorbance is An.

6. The inhibition rate calculation method of the in vitro non-enzymatic saccharification reaction comprises the following steps:

the experimental results are shown in table 2:

TABLE 2

Glycosylation products	Fructosamine product inhibition (%)	Inhibition of AGEs products (%)
			Control sample-1	1.57	0.47
Control sample-2	50.79	19.43
			Control sample-3	60.73	50.24
Control sample-4	28.80	20.38
			Control sample-5	66.49	64.45
Control sample-6	32.46	14.69
			Control sample-7	9.95	9.48
Example sample-1	71.20	67.77
			Example sample-2	82.72	81.52
Example sample-3	94.24	89.57

Conclusion: as can be seen from the control sample-2, the production of fructosamine products was effectively inhibited at the early stage when only glycosylation reaction was prevented, and the inhibition rate was 50.79%, but the production of AGEs, which was a saccharification product, was further increased with the increase of time, and the inhibition rate was decreased. From the control sample-5, it was found that fructosamine and AGEs can be effectively inhibited from being produced when both prevention and repair are simultaneously performed, and the inhibition rates are 66.49% and 64.45%, respectively. It can be seen from example-2 that fructosamine and AGEs can be more effectively inhibited from being generated when three directions of prevention, reversion and repair are combined, and inhibition rates are 82.72% and 81.52%, respectively.

The combination effect is calculated by adopting a golden average method, and the calculation formula is q=E _A+B /(E _A +E _B -E _A *E _B ) Wherein q is increased by more than 1.15 to 20. Control 2 (E) _A ) With control 6 (E) _B ) Comparative example 2 (E) _A+B ) Q values of 1.24 and 2.60 for the inhibited fructosamine and AGEs products, respectively, indicate that the active combination of control 2 has an enhanced active effect compared to the active combination of control 6. Control 3 (E) _A ) With control sample 4 (E) _B ) Comparative example 2 (E) _A+B ) Q values of 1.15 and 1.35 for the inhibited fructosamine products and AGEs products, respectively, were obtained, indicating that the active combination in control 3 had an enhanced active effect with the active combination of control 4.

Human efficacy evaluation (moisture content improvement, erythema improvement, yellowness improvement, elasticity improvement, etc.)

1. Test purpose: single-center development test, through the method of using products for 28 days by 50 persons in total in 10 groups continuously and testing the products by an instrument, the anti-glycosylation efficacy of the products is verified by front and back comparison.

2. Test sample

2.1 sample application method

TABLE 3 Table 3

2.2 study sample requirement

Ensuring that the sample is used under the conditions prescribed by the protocol does not present a predictable risk of harm to the health of the subject.

The test sample needs to be packaged and labeled in the following manner:

-class name

Expiration date or date of use after uncapping (if applicable)

Storage conditions (if applicable)

-other information (if applicable)

To improve traceability, the following information will be added for each test sample:

study number

Subject numbering

Use site (if applicable)

3. A subject

3.1. All subjects voluntarily engaged in the test, who have signed an informed consent, received verbal and papery informed consent in accordance with local regulations, procedures. Informed consent accounts for the nature, purpose, and potential risk of participating in the study, and emphasizes the voluntary nature of participating in the test, from which the subject may withdraw from the study for any reason. All subjects can be asked about the study, giving sufficient time consideration prior to signing. All informed consent signs must be made before the study begins.

3.2. Criteria for inclusion

(1) Chinese people

(2) Age 20-55 years (test starting time)

(3) The subject should be insensitive to common cosmetics

(4) Subjects did not participate in additional clinical studies for nearly three months

3.3. Exclusion criteria

(1) During the experiment, there is an outgoing travel planner

(2) Antihistamines used in the last week or immunosuppressants used in the last month

(3) Any anti-inflammatory drug is administered to the subject at the site of approximately two months

(4) Insulin dependent diabetes mellitus patient

(5) Respiratory disease patients undergoing treatment

(6) Women in lactation or gestation period

(7) Allergic constitution, allergic dermatitis, etc., with skin diseases or disease history

(8) The population undergoing dermatological treatment, or the subject taking hydroxy acids, whitening and anti-aging drugs for one month

(9) The test area has skin characterization with large area of mole, scratch, white spot, nevus pigmentosus, keloid, etc. affecting test

3.4. Limiting matters

(1) Treatment for inhibiting influence test on tested part during test

(2) During testing, use of other skin care products at the test site and other products affecting the test are prohibited

(3) During the test, daily necessities such as bath foam, soap and shampoo are consistent with those used before the test is started, and the replacement is forbidden

3.5. Selecting 50 persons of qualified subjects according to the target number, and ensuring that 50 persons are finally finished;

3.6. subjects failed the screening and replaced regular non-enrolled subjects, i.e., subjects signed informed consent, but failed to enroll because the inclusion/exclusion criteria were not met. Subjects leave, i.e., shed, after randomization or assignment into groups. Subjects who did not complete the study for any reason were considered to be shed, which was no longer supplemental.

Drop criteria:

subject shedding consent: the subject may exit for any reason at any time. (according to the Helsinki claim),

adverse events/serious adverse events: any study performed on the trial as perceived by the investigator was adverse to the subject,

-not follow a scheme

Subject interview

-other reasons: reasons for withdrawal of other subjects

In other cases, the investigator believes that continued participation in the trial is detrimental to the subject; CRF forms must be filled out until the screening fails or falls off. All subjects who had to end the trial early had to be recorded on a flow chart by the researcher or research team, and the last page "end the study", as well as the adverse event table and/or combination therapy table.

4. Test instrument

4.1. Cornemeter CM825 (Courage & Khazaka, germany)

4.2. Skin melanin and heme tester Mexameter MX18 (Courage & Khazaka, germany)

4.3. Skin elasticity tester PVM600 (Coura & Khazaka, germany)

4.4. Face image analyzer VISIA-CR (Canfield, U.S.A.)

5. Test environment

Environmental requirements: the temperature is 22.0 ℃ plus or minus 1.0 ℃; humidity 50% + -10%

6. Test procedure

6.1. Design of experiment for 28 days every other day

6.2. Test procedure

(1) For the first visit, subjects were subjected to a trial description and signed with informed consent.

(2) The subjects participating in the test are screened according to the test requirement, 50 subjects are screened into the group, and finally 50 subjects are guaranteed to be finished.

(3) The test of subjects with qualified screening is not possible to use skin care products in the morning. After the face was cleaned with clear water, it was allowed to rest for 30 minutes in the test environment. After 30 minutes, the face was tested with the instrument. The testers were divided into 10 groups of 5 persons each according to the test results, ensuring that the base numerical differences of each group were not more than 3%.

(4) After the test is completed, the test subjects are instructed to use the product, after listening to the instruction, the test subjects dispense the product, and the test samples are used at home for 28 consecutive days. During this period, subjects conducted a conference call back at 14 and 28 days after product use as instructed by the test, and then conducted a face test as per step (3).

6.3. Test sample life 28 days apart

6.4. Observing/testing the face of a part

6.5. Test schedule

TABLE 4 Table 4

6.6. Observation/test item

The test subjects were tested on the apparatus 3 times before use, 14 days after use, and 28 days after use.

(1) Stratum corneum moisture content: the average was taken 3 times using a Corneometer test. The skin moisture content before use was denoted as W0, and the skin moisture content on the nth day was denoted as Wn.

Parameter interpretation: the greater the test value, the higher the moisture content of the stratum corneum.

And (3) result judgment: after the product is used, the moisture content of the horny layer in the test area is obviously increased, which indicates that the test product has the moisturizing effect.

Skin moisture increase = (Wn-W0)/W0 x 100%

(2) Skin erythema: the mean was taken 3 times using a Mexameter test. Skin erythema before use was noted as Ery0 and erythema on day n was noted as Eryn. Parameter interpretation: the lower the test value, the lower the erythema content in the skin.

And (3) result judgment: after the product is used, the erythema in the test area is obviously reduced, which means that the tested sample has the effects of reducing the erythema value of the skin and improving the skin inflammation.

Reduction of skin erythema = (eri 0-eri n)/eri 0 x 100%

(3) Skin elasticity value: the PVM600 test was used.

Parameter interpretation: the higher the skin elasticity test value, the better the skin elasticity is;

and (3) result judgment: after the product is used, the skin elasticity value of the test area is obviously increased, which indicates that the tested sample has the effect of improving the skin elasticity;

skin elasticity increase = (Rn-R0)/R0 x 100%

(4) Skin yellowness b values: image Pro Plus analysis was photographed using VISIA-CR.

Parameter interpretation: the lower the skin yellowness b value, the lower the skin yellowness;

and (3) result judgment:

the product has effect in improving skin brightness; after the product is used, the skin yellowness b value of the test area is obviously reduced, which indicates that the tested sample has the effect of reducing the skin yellowness;

reduction in skin yellowness = (b 0-b n)/b0×100%

7. Test results

7.1 increase in skin moisture content

TABLE 5

As can be seen from the human body test results of the increase of the moisture content of the skin, the moisture content of the skin is continuously improved along with the combined action of a plurality of dimensions, which indicates that the repair of the barrier function of the skin is improved. In example-2, the moisture content of the skin was increased by 22.72% after 14 days, and the moisture content of the skin was increased to 31.39% after 28 days, indicating that the structural stability of the skin was improved without further deterioration.

7.2 reduction of skin erythema

TABLE 6

As can be seen from the human body test results of the reduction of the skin erythema, the reduction of the skin erythema is continuously increased along with the combined action of a plurality of dimensions, namely, the skin erythema is effectively improved. Indicating that the skin inflammation problem is alleviated. After 14 days in the example-2, the reduction of skin erythema is 23.61%, the reduction of erythema after 28 days is 30.70%, and the erythema caused by skin inflammation is relieved by multi-dimensional superposition, so that the damage of inflammatory factors and glycosylation reaction induced by free radicals to tissue structures is reduced.

7.3 increase in skin elasticity

TABLE 7

The human body test result of the increased skin elasticity shows that the increased skin elasticity is continuously increased along with the combined action of a plurality of dimensions, which indicates that the glycosylation reaction of the collagen of the skin is effectively inhibited. After 14 days in example-2, the increase of skin elasticity is 11.96%, and after 28 days, the increase of skin elasticity is 16.64%, and the glycosylation reaction of the collagen of the skin is relieved by the multi-dimensional superposition aiming at the consideration of different stages of the glycosylation reaction, so that the consumption of the collagen by the glycosylation reaction is reduced, and the problem of skin elasticity is improved.

7.4 reduction in skin yellowness

TABLE 8

/>

As can be seen from the results of the human body test with reduced skin yellowness, the reduced skin yellowness is continuously increased along with the combined action of multiple dimensions, which shows that the problem of skin yellowing caused by glycosylation reaction of collagen of the skin can be effectively inhibited. After 14 days in example-2, the reduction of skin yellowness was 9.20% and after 28 days the reduction of yellowness was 16.17%, the glycosylation reaction of the collagen of the skin was relieved by the multi-dimensional superposition for the different stages, and the skin yellowness was reduced.

From the results obtained in the above experiments, the various components in the examples play an important role, and are indispensable for achieving skin improvement in various aspects.

Stability test

TABLE 9

/>

The stability test shows that the auxiliary materials are reasonably selected, and the stability of the active substances can be maintained. In addition, although the effect of example 3 is better than that of example 2, the stability of the composition with a higher concentration of the active substance and a lower concentration is poor from the results of temperature cycle, accelerated light test and high temperature test for 1 month, the discoloration phenomenon occurs faster, and the stability of the shelf life of the product is affected when the composition is applied in the product.

The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.

Claims

1. The composition comprises the following components in parts by mass:

2. use of the composition of claim 1 for the preparation of a product for inhibiting protein glycation reactions.

3. Use of the composition of claim 1 for the preparation of anti-aging cosmetics.

4. The use according to claim 3, wherein said anti-aging comprises: reducing skin erythema, reducing skin yellowing, increasing skin moisture content, and/or increasing skin elasticity.

5. An anti-aging cosmetic comprising the composition of claim 1.

6. The cosmetic according to claim 5, wherein the composition according to claim 1 has a mass fraction of 1.8% -19.5%.

7. The cosmetic according to claim 5, characterized by comprising the following components in percentage by mass:

/>

8. the method for producing a cosmetic according to any one of claim 5 to 7, characterized in that,

step 1: sequentially adding glycerol, 1, 2-pentanediol, butanediol, PEG/PPG-17/6 copolymer, acrylic acid (esters)/C10-30 alkanol acrylate cross-linked polymer and PEG-11 methyl ether polydimethylsiloxane into water, stirring and dissolving;

step 2: adding arginine at 75deg.C, stirring for dissolving, and vacuum maintaining for 10min;

step 3: and cooling to 40-45 ℃, sequentially adding ALISTIN, symCalmin, ectoin, methyl silanol mannuronate, black tea extract, carnosine, extremely-repaired peptide and PHL, stirring and dissolving to prepare the cosmetic.

9. The method according to claim 8, wherein,

the stirring condition in the step 1 is 10-40HZ, heating to 75 ℃ and stopping stirring;

the stirring condition in the step 2 is 10-30HZ, and stirring is carried out until the mixture is dissolved;

and (3) stirring for 5min under the condition of 10-30 HZ.